Last reviewed · How we verify
ADAKVEO (CRIZANLIZUMAB-TMCA)
ADAKVEO (generic name: CRIZANLIZUMAB-TMCA) is a Selectin Blocker [EPC] drug developed by NOVARTIS PHARMS CORP. It is currently FDA-approved for Vaso-occlusive crisis in sickle cell disease.
ADAKVEO is a P-selectin blocker, classified as a monoclonal antibody. It is used to treat patients with sickle cell disease who experience frequent vaso-occlusive crises.
At a glance
| Generic name | CRIZANLIZUMAB-TMCA |
|---|---|
| Sponsor | NOVARTIS PHARMS CORP |
| Drug class | Selectin Blocker [EPC] |
| Target | P-selectin |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Vaso-occlusive crisis in sickle cell disease
Common side effects
- Headache
- Arthralgia
- Nausea
- Back pain
- Fatigue
- Abdominal pain
- Pyrexia
- Diarrhea
- Vomiting
- Oropharyngeal pain
- Pruritus
- Myalgia
Serious adverse events
- Pyrexia
- Pain
Key clinical trials
- A Trial of Crizanlizumab for the Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL) (Phase 2)
- A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Thera (Phase 3)
- An Open Label Phase 2 Study of Intravenously Administered Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADAKVEO CI brief — competitive landscape report
- ADAKVEO updates RSS · CI watch RSS
- NOVARTIS PHARMS CORP portfolio CI
Frequently asked questions about ADAKVEO
What is ADAKVEO?
What is ADAKVEO used for?
Who makes ADAKVEO?
What is the generic name of ADAKVEO?
What drug class is ADAKVEO in?
What development phase is ADAKVEO in?
What are the side effects of ADAKVEO?
What does ADAKVEO target?
Related
- Drug class: All Selectin Blocker [EPC] drugs
- Target: All drugs targeting P-selectin
- Manufacturer: NOVARTIS PHARMS CORP — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Vaso-occlusive crisis in sickle cell disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing